A Phase II Add-on Study of Vorinostat (VOR) in Higher Risk Myelodysplastic Syndrome with Failure of Hypomethylating Agents (HMA): The GFM Azavor Study

被引：0
|
作者：
Prebet, Thomas [1 ,2 ]
Delaunay, Jacques [3 ]
Wattel, Eric [4 ]
Braun, Thorsten [5 ]
Cony-Makhoul, Pascale [6 ]
Dimicoli, Sophie [7 ]
Wickenhauser, Stefan [8 ]
Lejeune, Julie [9 ]
Chevret, Sylvie [10 ]
Chermat, Fatiha [11 ]
Fenaux, Pierre [2 ,12 ,13 ]
Vey, Norbert [14 ]
机构：
[1] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT 06510 USA
[2] Grp Francophone Myelodysplasies, Paris, France
[3] Nantes Univ Hosp, Dept Hematol, Nantes, France
[4] Univ Lyon 1, F-69365 Lyon, France
[5] CHU Avicenne, Hematol Clin, Bobigny, France
[6] Ctr Hosp Annecy Genevois, Dept Hematol, Metz, France
[7] CHU Bordeaux, Serv Hematol, Pessac, France
[8] CH Nimes, Nimes, France
[9] Hop St Louis, AP HP, Paris, France
[10] Stat St Louis Hosp, Paris, France
[11] Hop St Louis, GFM, Paris, France
[12] Univ Paris 07, Hop St Louis, Serv Hematol Seniors, Paris, France
[13] Univ Paris 08, Hop Avicenne, Serv Hematol Clin, Bobigny, France
[14] Inst J Paoli I Calmettes, Hematol, F-13009 Marseille, France
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Azacitidine (AZA) Combined with Idarubicin in Higher Risk MDS - Results of a Phase I/II Study By the Groupe Francophone Des Myelodysplasies (GFM)
    Sebert, Marie
    Stamatoullas, Aspasia
    Braun, Thorsten
    Delaunay, Jacques
    de Renzis, Benoit
    Jeddi, Ramzi
    Meddeb, Balkis
    Berger, Mathilde Hunault
    Samey, Benedicte
    Chermat, Fatiha
    Chevret, Sylvie
    Chaffaut, Cendrine
    Fenaux, Pierre
    Ades, Lionel
    BLOOD, 2015, 126 (23)
  • [42] Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic Syndrome
    Chien, Kelly S.
    Borthakur, Gautam
    Naqvi, Kiran
    Daver, Naval
    Bravo, Guillermo Montalban
    Cortes, Jorge E.
    DiNardo, Courtney D.
    Jabbour, Elias
    Alvarado, Yesid
    Andreeff, Michael
    Bose, Prithviraj
    Jain, Nitin
    Sheppard, Kimberly
    Klingner-Winton, Cheri
    Pierce, Sherry A.
    Dong, Xiao Qin
    Soltysiak, Kelly A.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2020, 136
  • [43] Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM
    Natarajan-Ame, Shanti
    Park, Sophie
    Ades, Lionel
    Vey, Norbert
    Guerci-Bresler, Agnes
    Cahn, Jean-Yves
    Etienne, Gabriel
    Bordessoule, Dominique
    Ravoet, Christophe
    Legros, Laurence
    Cheze, Stephane
    Stamatoullas, Aspasia
    Berger, Elisabeth
    Schmidt, Aline
    Charbonnier, Aude
    Chaury, Marie-Pierre
    Braun, Thorsten
    Fenaux, Pierre
    Dreyfus, Francois
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (02) : 232 - 237
  • [44] Phase I-II Study of Bendamustine in Patients With Acute Leukemia and High Risk Myelodysplastic Syndrome
    Chacar, Christelle
    Jabbour, Elias
    Ravandi, Farhad
    Borthakur, Gautam
    Kadia, Tapan
    Estrov, Zeev
    Rios, Mary Beth
    Cortes, Jorge
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (03): : 197 - 200
  • [45] Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study.
    Zeidan, Amer M.
    Hu, Xin
    Long, Jessica B.
    Wang, Rong
    Huntington, Scott F.
    Podoltsev, Nikolai Alexandrovich
    Giri, Smith
    Stahl, Maximilian
    Gore, Steven
    Ma, Xiaomei
    Davidoff, Amy J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Evaluation of ON01910.Na In Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study
    Silverman, Lewis R.
    Navada, Shyamala C.
    Odchimar-Reissig, Rosalie
    Najfeld, Vesna
    Ohnuma, Takao
    Wilhelm, Francois
    Reddy, E. Premkumar
    Holland, James F.
    BLOOD, 2010, 116 (21) : 1214 - 1214
  • [47] Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients with Myelodysplastic Syndromes (MDS) after Failure of Hypomethylating Agent-Based Therapy
    Lee, Sangmin
    Desai, Pinkal
    Edirisinghe, Bianca
    Pianello, Samantha
    Singer, Jack W.
    Samuel, Michael
    Ritchie, Ellen K.
    Roboz, Gail J.
    BLOOD, 2017, 130
  • [48] Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS)
    Morita, Kiyomi
    Bravo, Guillermo Montalban
    Sasaki, Koji
    Bodden, Kristy R.
    Wang, Feng
    Bose, Prithviraj
    Alvarado, Yesid
    Daver, Naval
    Borthakur, Gautam
    Ravandi, Farhad
    Takahashi, Koichi
    Jabbour, Elias
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Ohanian, Maro
    Pierce, Sherry A.
    Azab, Mohammad
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2020, 136
  • [49] A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM)
    Ades, Lionel
    Guerci-Bresler, Agnes
    Cony-Makhoul, Pascale
    Legros, Laurence
    Sebert, Marie
    Braun, Thorsten
    Delaunay, Jacques
    Desseaux, Kristell
    Chevret, Sylvie
    Fenaux, Pierre
    HAEMATOLOGICA, 2019, 104 (04) : E131 - E133
  • [50] Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome:: A multicenter phase II study in elderly patients
    Wijermans, P
    Lübbert, M
    Verhoef, G
    Bosly, A
    Ravoet, C
    Andre, M
    Ferrant, A
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (05) : 956 - 962
12345